Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

Eligibility Criteria

• * Provision of signed and dated informed consent form
• * Stated willingness to comply with all study procedures and availability for the duration of the study
• * Radiologic and other clinical evidence leading to a diagnosis of NCFBE
• * 1 CF-causing mutation and/or sweat chloride measurement ≥ 30 mEq/L and \< 60 mEq/L
• * Able to perform spirometry meeting American Thoracic Society (ATS) criteria for acceptability and repeatability, and FEV1 40-90% predicted
• * Clinically stable in the past 4 weeks with no evidence of bronchiectasis exacerbation
• * Willingness to use at least one form of acceptable birth control including abstinence or condom with spermicide. This will include birth control for at least one month prior to screening and agreement to use such a method during study participation for an additional four weeks after the last administration of Study Drug
• * Ability to take Trikafta
• * Agreement to adhere to all current medical therapies as designated by the study physician
• * Diagnosis of cystic fibrosis
• * Documented history of drug or alcohol abuse within the last year
• * Pulmonary exacerbation or changes in therapy for pulmonary disease in the 4 weeks prior to screening
• * Listed for lung or liver transplant at the time of screening
• * Cirrhosis or elevated liver transaminases \> 3 times the upper limit of normal (ULN)
• * Pregnant or breastfeeding
• * Inhibitors or inducers of CYP3A4, including certain herbal medications and grapefruit/grapefruit juice, or other medicines known to negatively influence Trikafta administration
• * History of solid organ transplant
• * Active therapy for non-tuberculosis mycobacterial infection or any plan to initiate non-tuberculosis mycobacterial therapies during the study period
• * Known allergy to Trikafta
• * Treatment in the last 6 months with an approved CFTR modulator
• * Any other condition that in the opinion of the lead investigators might confound results of the study or pose an additional risk from administering Study Drug
• * Treatment with another investigational drug or other intervention within one month prior to enrollment, throughout the duration of study participation, and for an additional four weeks following final drug administration
• * Evidence of cataract/lens opacity determined to be clinically significant by an ophthalmologist at or within 3 months prior to the Screening Visit